Lessons Learned From Antiobesity Medication Withdrawal Trials
The use of glucagon-like peptide (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP)/GLP-1 receptor agonists, such as tirzepatide, continues to climb amidst patient demand and a growing set of clinical indications for treatment. As specialists and primary care clinicians adopt these medications, they need to be well-versed in the clinical benefits and risks of both starting and […]
Guiding Obstetric Care and Treatment Decisions for Women With Prior GLP-1 Receptor Agonist Use
Glucagon-like peptide-1 receptor agonists (GLP-1RAs), such as liraglutide and semaglutide, have revolutionized treatment of obesity. Obesity and obesity-related comorbidities increase the risks of adverse outcomes such as miscarriage, congenital malformations, preterm birth, gestational diabetes, and preeclampsia, which can have significant long-term consequences for mother and infant. By enabling women to begin pregnancy at a lower […]
Increasing Postpartum Use of GLP-1 Receptor Agonists
This study uses data from the Danish Medical Birth Register to examine postpartum use of glucagon-like peptide 1 receptor agonists.
Gestational Weight Gain and Pregnancy Outcomes After GLP-1 Receptor Agonist Discontinuation
This cohort study examines gestational weight gain and pregnancy outcomes after glucagon-like peptide-1 (GLP-1) receptor agonist discontinuation.
Eli Lilly 1st pharma company to reach $1 trillion market cap
Indianapolis-based Eli Lilly is the first publicly traded U.S. healthcare company to reach market capitalization over $1 trillion, elevating the drugmaker to an exclusive list dominated by tech giants. Eli Lilly’s shares peaked Nov. 21, giving the pharmaceutical company market capitalization above $1 trillion before slightly dipping to $950 billion, according to The Wall Street […]
Readout of Phase 3 Semaglutide Trials Marks Critical Moment in Alzheimer’s Research and Suggests Potential for Combination Therapies
Data provides new insights into targeting the diverse pathobiology of Alzheimer’s disease, an approach spearheaded by the ADDF NEW YORK, Nov. 24, 2025 /PRNewswire/ — Today, Novo Nordisk released topline results from their phase 3 Evoke and Evoke+ trials of semaglutide, an oral GLP-1…
Novo Nordisk Shares Slump After Ozempic Pill Fails in Alzheimer’s Trials – The Wall Street Journal
Novo Nordisk Shares Slump After Ozempic Pill Fails in Alzheimer’s Trials The Wall Street JournalView Full Coverage on Google News
Ozempic Pill Flops in Major Trials for Alzheimer’s
An oral version of the GLP-1 drug semaglutide failed to significantly slow the disease’s progression compared to a placebo.
The complicated relationship between GLP-1s and pregnancy
A new study sheds light on the risks and benefits of taking GLP-1 weight-loss drugs before having a baby.
STAT+: Lilly hits trillion-dollar valuation as GLP-1 era peaks
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Morning! We’re closing in on CMS’s deadline for 2027 Medicare-negotiated drug prices. Plus, we see a break from precedent in how the FDA selects priority review vouchers, and more. Can a GLP-1 drug slow Alzheimer’s […]